A new major trial shows that beta-blockers don't provide any real benefit to people with the most common form of heart attack.
A common treatment given after heart attacks may not be worthwhile for a large segment of the population. New trial data finds that most people who suffer a heart attack do not benefit from taking beta-blockers afterward.
A large international team of researchers conducted the trial, which compared the outcomes of nearly 10,000 heart attack patients who were either given beta-blocker therapy or not.On average, people with preserved heart function given beta-blockers were no less likely to die or to experience a second heart attack than those not given beta-blockers, the researchers found. Secondary data also showed that women might actually face a higher risk of complications from taking these medications. “This trial will reshape all international clinical guidelines,” said senior study author Valentin Fuster, president of Mount Sinai Fuster Heart Hospital, in ahave been a key aspect of treating and managing cardiovascular disease. These drugs block the effects of adrenaline on the body’s beta-receptors, which then reduces heart rate and lowers blood pressure . They’re often used to reduce stress on a badly damaged heart following a heart attack , in theory lowering the risk of a second heart attack or other cardiovascular issues. But heart medicine has evolved greatly since the arrival of the first beta-blockers in the 1960s. New treatments and improved knowledge have made it easier for doctors to prevent these infarctions from causing as much damage to the heart as before. And that’s led some researchers to wonder whether beta-blockers should still be considered a front-line treatment following heart attacks, including the team behind this large new trial.The team’s trial, named REBOOT, involved roughly 8,500 people. The patients had all experienced relatively mild heart attacks and appeared to have a left ventricular ejection fraction above 40%. LVEF measures how well our left ventricle pumps out blood. A healthy LVEF is typically considered above 51%, while slightly reduced function is between 40% and 50%. Half of the patients were randomized to receive beta-blockers after being discharged from the hospital, while the other half received none. Both groups were then tracked for several years . By the study’s end, there wasn’t any significant difference in outcomes between the two groups. Deaths , secondary heart attacks, and hospitalizations from heart failure occurred just as often in the beta-blocker group as they did in the control group.over the weekend in the New England Journal of Medicine—indicate that beta-blockers shouldn’t be a standard treatment for most heart attack patients, the researchers say.While beta-blocker therapy may be worthless for most male heart attack patients, it could be actively dangerous to women in particular.in the European Heart Journal, women on beta-blockers had higher rates of heart attacks, hospitalization, and death than women not on the drug. On closer inspection, this added risk was only seen in women who maintained normal heart function . Though it’s not entirely clear why only women might experience this risk, studies have found that heart attacks canThe findings should better optimize the long-term care of heart attack patients, who are often already prescribed multiple medications to keep their cardiovascular health in check. “These results will help streamline treatment, reduce side effects, and improve quality of life for thousands of patients every year,” said lead author Borja Ibáñez, scientific director of Spain’s National Center for Cardiovascular Research , in a statement. That said, the REBOOT trial won’t bury beta-blockers for good. The drugs may still help prevent complications in people with severe heart attacks and areArtificial IntelligenceAs the AI chipmaker rockets past a $4 trillion valuation, CEO Jensen Huang lays out a stunning vision of a future with robot assistants and revived American factories, but admits the transition won't be painless.An AI That Promises to ‘Solve All Diseases’ Is About to Test Its First Human Drugs A secretive, Google-backed lab is using artificial intelligence to invent new medicines for humanity's worst illnesses. But can we trust drugs designed by a mind that isn't human?Yet Another Study Finds Weed Is Bad for Your HeartTech Utopians Are Using a Chinese-Built ‘Ghost City’ to Trial Their Network State FantasiesThe Winklevoss Twins Are Eyeing $2.22 Billion Crypto IPO
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Ozzy Osbourne died of a heart attack, death certificate showsThe death certificate for Ozzy Osbourne listed his occupation as 'Songwriter, Performer and Rock Legend.'
Read more »
Common Painkiller Tied to Heart Failure Risk in Older AdultsThe antiseizure medication pregabalin, which is commonly prescribed for noncancer pain, has been linked to an increased risk for heart failure, new data suggest.
Read more »
Heart-to-Heart | Chronic Pain and Heart HealthIf you’re living with chronic pain or know someone who is, doctors say your heart is likely being impacted too.Long-term pain can lead to sleep deprivation, inf
Read more »
Some women have higher risk of death on common heart attack medication, study findsThe gold standard drug treatment for heart attacks is ineffective for many and may increase the risk of death and disability in certain women, new studies find.
Read more »
Study: Common heart attack drug doesn't work, may raise risk of death for some womenA class of drugs called beta-blockers doesn't benefit the vast majority of patients and may contribute to a higher risk of hospitalization and death in some women, research found.
Read more »
Common Drug Better Than Aspirin For Repeat Heart Attacks, Study FindsThe Best in Science News and Amazing Breakthroughs
Read more »